21st North Inc  

(Public, OTCMKTS:ULGX)   Watch this stock  
Find more results for ULGX
0.00400
0.00000 (0.00%)
Delayed:   2:05PM EDT
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.00 - 0.00
52 week 0.00 - 0.15
Open 0.00
Vol / Avg. 101,000.00/113,983.00
Mkt cap 139,632.00
P/E     -
Div/yield     -
EPS -0.22
Shares 21.82M
Beta 2.57
Inst. own 19%

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -12.48% -53.45%
Operating margin -5.47% -48.68%
EBITD margin - -23.23%
Return on average assets -27.07% -83.63%
Return on average equity - -
Employees 61 -
CDP Score - -

Address

14405 21st Ave N
MINNEAPOLIS, MN 55447-4685
United States - Map
+1-612-4751400 (Phone)
+1-763-4048118 (Fax)

Website links

Description

21st North Inc., formerly Urologix Inc., was engaged in developing, manufacturing, marketing and distributing medical products. The Company offered its products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). The Company has no operations. The Company intends to dissolve.

Officers and directors

Gregory J. Fluet Chief Executive Officer, Director
Age: 45
Scott M Madson Chief Financial Officer
Age: 51
Lisa A. Ackermann Executive Vice President - Sales and Marketing
Age: 42
Mitchell Dann Independent Non-Executive Chairman of the Board, Lead Director
Age: 54
Christopher R. Barys Independent Director
Age: 48
Sidney W. Emery Jr. Independent Director
Age: 68
Patrick D. Spangler Independent Director
Age: 59